Christopher A. Rice

This paper develops and validates a LAMP assay for Balamuthia mandrillaris with high sensitivity and specificity, suitable for clinical use in resource-limited settings.

The paper tests virulence variation among Naegleria fowleri isolates using a mouse model and in vitro assays, finding significant differences in disease onset and mortality.

This study evaluates cyclic peptides as inhibitors of Balamuthia mandrillaris, finding eight compounds with IC50 <5 μM and minimal cytotoxicity.

The paper reports the structural determination of 19 N. fowleri proteins, identifying potential drug targets with structural differences from human homologs.

The paper identifies 59 compounds that inhibit Balamuthia mandrillaris growth and reconstructs its transcriptome to determine potential molecular targets for drug development.